Ethris and DZIF Ink Massive Vaccine Deal

Germany strengthens its biotech sovereignty as Ethris and DZIF partner to develop next-gen mRNA vaccines targeting bacteria and parasites 

5 May 2026

COVID-19 made mRNA vaccines famous. It also made them narrow. Most of the technology's promise has since been channelled into respiratory diseases, where the commercial case is easiest to make. A deal signed in February between Ethris, a Munich-based biotech, and the German Center for Infection Research (DZIF) quietly tries to correct that.

This partnership covers a notably broad range of threats: bacteria, parasites, and emerging pathogens alongside familiar viruses. At its core is access. DZIF gains the right to use Ethris's SNIM RNA system, a stabilised, low-immunogenic mRNA format, as well as its SNaP lipid nanoparticle delivery technology. Clinical-grade manufacturing will come from Evonik and Patheon, filling a gap that has long constrained academic research in Germany.

DZIF co-ordinates more than 700 researchers across 35 German institutions. Scientific depth it has. A direct route to GMP-grade mRNA production it did not, until now. In exchange, Ethris gains the clinical standing of a partner with a lead candidate already in Phase 2a development. Priority targets include pathogens linked to antimicrobial resistance and diseases that hit immunocompromised patients hardest, two areas where global health preparedness remains thin.

The logic of the arrangement reflects a wider pattern. Germany's mRNA ecosystem, already anchored by BioNTech and CureVac, has grown more by deliberate design than by accident. Structured partnerships between industrial manufacturers and public research bodies are, in the view of European policymakers, precisely how health resilience is built. The question is whether tying platform access to academic ambition produces usable vaccines, or just well-funded research agendas. Given how long the pipeline from pathogen to product tends to be, the answer will not arrive quickly.